Radiation for Breast Cancer: 603 Real Stories

603 stories match breast cancer and radiation. 562 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Triple-negative breast cancer first discovered through a duodenal metastasis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; CK7-positive; GATA3-positive; vimentin-positive; CDX2-negative; CK20-negative., triple negative

Metastatic Site: duodenum

She died two days after choosing comfort-focused care, following rapid decline from metastatic triple-negative breast cancer with duodenal involvement and small-bowel obstruction.

PubMed Central
OutcomeIn Memory
Jeanine, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Jeanine's Patient Story

Patient Info: Jeanine, Female | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; genetic testing negative

Jeanine completed chemotherapy, bilateral mastectomy, and post-surgery radiation after her disease was restaged from Stage II to Stage III, and she described continued active oncology care and advocacy as of June 2021.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
Susie's, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Susie's's Patient Story

Patient Info: Susie's daughter, Female, 40s

As of May 2021, Susie’s daughter was living after treatment for an 8 cm invasive lobular carcinoma and dealing with side effects from different endocrine therapies, while Susie became active in ILC advocacy and research support.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
MB
Breast Cancer

Male breast cancer discovered after years of stiff-person syndrome

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; anti-amphiphysin antibody positive at 1:64; hereditary cancer panel negative for pathogenic germline variants.

He completed curative-intent breast cancer treatment and reported substantial improvement in upper-body stiffness, although lower-extremity stiffness, cramps, and unsteadiness persisted.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Breast cancer returned in the stomach and peritoneum after three years in remission

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: Initial breast tumor: ER 95%, PR 5%, HER2-negative, Nottingham grade 2. Metastatic peritoneal tumor: ER 80%

Metastatic Site: stomach; peritoneum

After metastatic breast cancer was confirmed in the stomach and peritoneum, she chose palliative care and inpatient hospice and died a few weeks later.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Breast cancer with sarcoidosis that mimicked metastatic disease

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative.

Her most recent mammogram showed no recurrent breast cancer while she continued letrozole, goserelin, and six-monthly follow-up.

PubMed Central
OutcomeCancer-Free / NED
Hillary, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Hillary's Survivor Story

Patient Info: Hillary, Female, 50s

As of April 2021, Hillary had completed surgery, chemotherapy, radiation, lymphedema rehabilitation and staged reconstruction for node-positive breast cancer, with return toward normal life; no formal stage or NED status was stated.

Cleveland Clinic
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast cancer recurrence in the mandibular condyle causing jaw pain

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative.

Metastatic Site: right mandibular condyle with extension into the…

After anastrozole and 60 Gy of radiation, her jaw pain, mouth opening, and function improved, although some discomfort remained and palliative systemic treatment was continuing.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Breast CancerBreast Cancer

A BioZorb-Site Density Two Years After Lumpectomy Was Fat Necrosis

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A new density at the lumpectomy site was confirmed as fat necrosis rather than recurrent cancer during ongoing surveillance.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

A New Mass Three Years After Lumpectomy Was Fat Necrosis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A new mass detected three years after treatment was biopsy-proven fat necrosis rather than recurrent cancer.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

A Mass Beside a BioZorb Implant Was Fat Necrosis, Not Recurrence

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A 1.8 cm mass detected beside the BioZorb site was confirmed as fat necrosis, with continued imaging follow-up recommended.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Local Breast Cancer Recurrence Was Found During BioZorb Surveillance

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial right breast tumor: ER-positive, PR-positive, HER2-equivocal. Recurrent right breast tumor: ER-positive, HER2-negative.

Two sites of right-breast recurrence were confirmed three years after lumpectomy, leading to right mastectomy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Silicone lymphadenopathy after treatment for recurrent triple-negative breast cancer

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative; BRCA1-negative; BRCA2-negative; latest recurrence Ki-67 60%–70%.

At the May 2020 follow-up, biopsies confirmed silicone-related lymph-node changes rather than cancer, and imaging showed no recurrent disease while six-monthly surveillance continued.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

A difficult breast-reconstruction infection after breast cancer treatment

Patient Info: Anonymized, Female, 40s

After wide debridement and prolonged antibiotic treatment, the breast and abdominal wounds healed, imaging showed resolution of the subcutaneous infection, and no infection recurrence was seen over three years.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Ductal and lobular carcinoma in situ arising within a fibroadenoma

Patient Info: Anonymized, Female, 40s

Biomarkers: DCIS ER-positive and PR-positive; LCIS E-cadherin-negative.

Lumpectomy achieved tumor-free margins for the in situ disease, and she subsequently completed adjuvant radiation therapy.

PubMed Central
OutcomeNot reported
LA
Breast Cancer

Locally advanced male breast cancer associated with a pathogenic ATM variant

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: ER 100% positive; PR 100% positive; HER2-negative; Ki-67 30%; germline pathogenic ATM variant c.2921+1G>A.

Two years after diagnosis, he had an ECOG performance status of 0 and remained without signs of breast-cancer relapse or another primary cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed Central
OutcomeResponding Well
Cherie, who was diagnosed with Stage II Breast CancerBreast Cancer

Cherie's Stage 2 Breast Cancer Story After a Second Opinion

Patient Info: Cherie, Female, 50s | Stage II

Cherie described herself as being in remission while continuing hormone therapy. She remained concerned about relapse and used travel and painting to manage anxiety.

Our Cancer Stories
OutcomeCancer-Free / Remission
Onagh, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Onagh's Survivor Story

Patient Info: Onagh, Female | Stage III

Her stage 3 breast cancer was in complete remission, and she no longer required treatment.

Our Cancer Stories
OutcomeCancer-Free / NED
Harper, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Harper's Patient Story

Patient Info: Harper, Female, 50s | Stage IV

Harper was living with Stage IV breast cancer after self-funded private treatment that included mastectomy, lymphadenectomy, chemotherapy, and radiation therapy; she felt better than before diagnosis but still hoped for complete recovery.

Our Cancer Stories
OutcomeLiving With Cancer